Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indatraline is a non-selective monoamine reuptake inhibitor that blocks the reuptake of dopamine, norepinephrine (noradrenaline), and serotonin with similar efficacy to cocaine. It acts as an antidepressive agent and has been studied for its potential use in treating cocaine addiction due to its slower onset and longer duration of action compared to cocaine. Indatraline produces behavioral effects suggestive of enhanced dopaminergic, noradrenergic, and serotonergic activity in animal models. It has also been shown to block the action of methamphetamine and MDMA in laboratory experiments[1][2][3][4]. The compound is typically used experimentally rather than clinically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indatraline.